ENTA

In a report released today, Roanna Ruiz from SVB Securities maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report), with a price target of $50.00. The company's shares closed last Friday at $55.15. According to TipRanks.com, Ruiz 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -57.9% and a 5.9% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Atea Pharmaceuticals, and Aligos Therapeutics. Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $71.44, a 42.9% upside from current levels.
https://www.tipranks.com/news/blurbs/enanta-pharmaceuticals-enta-receives-a-hold-from-svb-securities-2?utm_source=advfn.com&utm_medium=referral